

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Kulkarni Samarth</u> _____ (Last) (First) (Middle) <u>C/O CRISPR THERAPEUTICS, INC.</u> <u>105 W FIRST STREET</u> _____ (Street) <u>BOSTON MA 02127</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG [CRSP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">Chief Executive Officer</p>
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/16/2022</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	08/16/2022		A		25,000		(2)	(2)	Common Shares	25,000	\$0.00	25,000	D	
Performance-based Restricted Stock Units	(3)	08/16/2022		A		150,000 ⁽⁴⁾		(5)	(5)	Common Shares	150,000	\$0.00	150,000 ⁽⁴⁾	D	

Explanation of Responses:

- Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- The restricted stock units shall vest in full on August 16, 2025, subject to continued service to the Company or any of its subsidiaries.
- Each performance-based restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- Represents the maximum number of shares of CRSP Common Shares that may be awarded upon the achievement of performance conditions.
- This grant is subject to both time- and performance-based vesting. Performance-based restricted stock units will vest subject to the terms and conditions of the grant agreement evidencing the award and the Company's 2018 Stock Option and Incentive Plan. The performance conditions shall be deemed satisfied subject to achievement of certain share price targets on or before the third anniversary of the date of grant. All of the performance-based restricted stock units that have satisfied the applicable performance-based criteria shall be deemed vested on the third anniversary of the date of grant, subject to continued service to the Company or any of its subsidiaries through such date.

Remarks:

/s/ Elizabeth Ryland Waldinger, 08/18/2022
attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.